← Back to Search

Anti-viral

Molnupiravir for COVID-19 (MOVe-AHEAD Trial)

Phase 3
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 29 days
Awards & highlights

MOVe-AHEAD Trial Summary

This trial is testing whether the study medication molnupiravir can prevent people from getting symptomatic COVID-19 disease. The study is double-blind, meaning that neither the participants nor the study staff will know who is receiving the study medication or the placebo. The trial will last for 28 days.

Eligible Conditions
  • COVID-19

MOVe-AHEAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~29 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 29 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Discontinuing From Study Therapy Due to AE
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Percentage of Participants With ≥1 Adverse Event
Secondary outcome measures
Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Percentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 29
+1 more

Side effects data

From 2022 Phase 2 & 3 trial • 1735 Patients • NCT04575597
4%
Diarrhoea
4%
COVID-19
1%
COVID-19 pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part 1: MK-4482 200 mg
Part 1: MK-4482 400 mg
Part 1: MK-4482 800 mg
Part 1: Placebo
Part 2: MK-4482 800 mg
Part 2: Placebo

MOVe-AHEAD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MolnupiravirExperimental Treatment1 Intervention
Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
Group II: PlaceboPlacebo Group1 Intervention
Participants take placebo Q12H on Days 1 to 5.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Molnupiravir
2022
Completed Phase 3
~4360

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,579,387 Total Patients Enrolled
6 Trials studying COVID-19
2,699 Patients Enrolled for COVID-19
Merck Sharp & Dohme LLCLead Sponsor
3,886 Previous Clinical Trials
5,052,112 Total Patients Enrolled
13 Trials studying COVID-19
6,899 Patients Enrolled for COVID-19
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,777 Previous Clinical Trials
8,061,045 Total Patients Enrolled
9 Trials studying COVID-19
3,097 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Florida
Colorado
Texas
How old are they?
65+
18 - 65
What site did they apply to?
Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508)
Santa Clara Family Clinic ( Site 2462)
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
2021. "Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04939428.
~666 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top